We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The FDA’s recent decision to drop an advisory panel member has opened the agency up to charges that it does not fairly apply its conflict-of-interest policies.
